Sonoma Pharmaceuticals (NASDAQ:SNOA) (NASDAQ:SNOA) is a specialty pharmaceutical company dedicated to the development, manufacturing and commercialization of prescription and over-the-counter products that address a broad range of skin conditions. The company’s portfolio centers on antimicrobial, anti-inflammatory and anti-fungal therapies designed for dermatological and medical applications. Through both branded and generic offerings, Sonoma serves patients and healthcare providers seeking treatments for acne, rosacea, onychomycosis, impetigo and other skin disorders.
In the prescription segment, Sonoma markets specialty topical formulations and systemic pharmaceuticals, often leveraging proprietary delivery technologies to enhance efficacy and compliance. Its over-the-counter business includes medicated cleansers, antiseptic washes and everyday skin health products. The company also provides contract manufacturing services for external partners, offering formulation expertise, regulatory support and U.S. Food and Drug Administration–compliant production capacity at its California facilities.
Founded in the late 1960s as a small-scale manufacturer serving regional dermatology practices, Sonoma has expanded through strategic acquisitions and technology alliances. Today, its products are sold in North America, Europe, the Middle East and select Asia-Pacific markets, often via distribution agreements with multinational pharmaceutical and consumer health companies. The company’s international reach is bolstered by in-house regulatory, medical affairs and quality assurance teams that facilitate market entry and product lifecycle management.
Headquartered in Campbell, California, Sonoma Pharmaceuticals is led by Chief Executive Officer Raymond Lee, who has overseen the company’s transition into specialty and generic dermatology since 2015. Supported by a senior management team with deep experience in research and development, manufacturing and commercial strategy, Sonoma continues to invest in novel topical technologies and expanded clinical programs aimed at addressing unmet needs in skin health.
